{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:08:40Z","timestamp":1718496520696},"reference-count":84,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,5,21]],"date-time":"2007-05-21T00:00:00Z","timestamp":1179705600000},"content-version":"vor","delay-in-days":1542,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:p> <jats:italic>The goal of antihypertensive therapy is to provide effective treatment that can be sustained lifelong, while lowering elevated blood pressure and preventing hypertensive end\u2010organ damage and mortality. Angiotensin\u2010converting enzyme (ACE) inhibitors and angiotensin II antagonists (AIIAs) control blood pressure as well as other available classes of antihypertensive drugs. The ACE inhibitors have been demonstrated to reduce the incidence of stroke, reverse left ventricular hypertrophy, and improve congestive heart failure symptomatology and mortality to a similar degree as diuretics and \u03b2\u2010adrenergic blockers. ACE inhibitors reduce postmyocardial infarction recurrence, improve congestive heart failure symptomatology and mortality, and slow the progression of glomerular renal disease. The AIIAs reverse left ventricular hypertrophy. Several of these agents have been shown to improve congestive heart failure symptomology and mortality, to reduce the occurrence of early atherosclerotic vascular disease, and to slow the progression of renal failure in type 2 diabetes mellitus nephropathy. One AHA has reduced the incidence of end\u2010stage renal disease in non\u2010insulin\u2010dependence diabetes mellitus nephropathy over 3 years. Ideally, antihypertensive therapy should maintain or improve the patient's quality of life without creating side effects or adverse laboratory effects. Among the available nine classes of antihypertensive drugs, ACE inhibitors and the AIIAs come close to meeting the description of an ideal drug. AIIAs and ACE inhibitors, two classes of antihypertensive drugs that reduce the activity of the renin\u2010angiotensin II system, should be among the preferred first\u2010step drugs for the treatment of hypertension.<\/jats:italic> <\/jats:p>","DOI":"10.1111\/j.1524-6175.2003.01040.x","type":"journal-article","created":{"date-parts":[[2007,5,21]],"date-time":"2007-05-21T17:22:49Z","timestamp":1179768169000},"page":"137-144","source":"Crossref","is-referenced-by-count":7,"title":["Drugs That Interrupt the Renin\u2010Angiotensin System Should Be Among the Preferred Initial Drugs to Treat Hypertension"],"prefix":"10.1111","volume":"5","author":[{"given":"Michael A.","family":"Moore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,5,21]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440420033005"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/08037059309077529"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.9.1140"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2001.00468.x"},{"key":"e_1_2_11_6_2","unstructured":"Hypertension Control Rates.Health Plan Employer Data and Information Set (HEDIS) National Quality Assurance Committee. 2003 Annual Report. Available at:www.ncqa.org. Accessed February 6 2002."},{"key":"e_1_2_11_7_2","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/archinte.161.12.1480","article-title":"What is goal blood pressure for the treatment of hypertension","volume":"161","author":"Kaplan NM","year":"1992","journal-title":"Arch Intern Med"},{"issue":"4","key":"e_1_2_11_8_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0149-2918(98)80130-6","article-title":"Continuation of initial antihypertensive medication after one year therapy","volume":"20","author":"Bloom BS","year":"1998","journal-title":"Clin Ther"},{"key":"e_1_2_11_9_2","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/S0149-2918(01)80152-1","article-title":"Four\u2010year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive classes","volume":"23","author":"Conlin PR","year":"2002","journal-title":"Clin Ther"},{"key":"e_1_2_11_10_2","volume-title":"USRDS 2002 Annual Report","author":"US Renal Data System"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.37.4.1047"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1996.00440150033003"},{"key":"e_1_2_11_13_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/archinte.159.1.23","article-title":"Current strategies for management of hypertensive renal disease","volume":"159","author":"Moore MA","year":"1996","journal-title":"Arch Intern Med"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198211000-00014"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1992.383"},{"issue":"14","key":"e_1_2_11_16_2","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1097\/00005344-198900000-00012","article-title":"Angiotensin converting enzyme inhibition: discrepancy between antihypertensive effect and suppression of enzyme activity","volume":"4","author":"Waeber B","year":"1989","journal-title":"J Cardiovasc Pharm"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.20.2658"},{"issue":"43","key":"e_1_2_11_18_2","first-page":"501","article-title":"Hypertension trials: 1990 to 2000","volume":"10","author":"Kaplan NM","year":"2000","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)80413-5"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)00237-X"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(96)80212-8"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000997"},{"issue":"3","key":"e_1_2_11_23_2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00002512-200118030-00007","article-title":"Antihypertensive treatment in elderly patients aged 75 years or over: a 24 week study of the tolerability of candesartan cilexetil in relationship to hydrochlorothiazide","volume":"18","author":"Neldam S","year":"2001","journal-title":"Drugs Aging"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000615"},{"issue":"1","key":"e_1_2_11_25_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1185\/03007999909115169","article-title":"Effects of eprosartan versus enalapril in hypertensive patients on the renin\u2010angiotensin\u2010aldosterone system and safety parameters: results 26 week double blind, multicenter study","volume":"15","author":"Gavras I, Gavras H, and The Eprosartan Study Group","year":"1999","journal-title":"Curr Med Res Opinion"},{"key":"e_1_2_11_26_2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jama.1967.03130240070013","article-title":"Veterans Administration Cooperative Study Group on Antihypertensive Agents: effects of treatment on morbidity in hypertension. Results in patients with diastolic averaging 115 through 129 mm Hg","volume":"202","author":"Veterans Administrative Cooperative Study Group","year":"1967","journal-title":"JAMA"},{"key":"e_1_2_11_27_2","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jama.1970.03170330025003","article-title":"Veterans Administration Cooperative Study Group on Antihypertensive Agents: effects of treatment on morbidity in hypertension. Results in patients with diastolic averaging 90 through 114 mm Hg","volume":"213","author":"Veterans Administration Study Group","year":"1970","journal-title":"JAMA"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03460240051027"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.23.2981"},{"key":"e_1_2_11_30_2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in the hypertension study (LIFE): a randomized trial against atenolol","volume":"359","author":"Dahloft B","year":"2002","journal-title":"Lancet"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)10327-1"},{"key":"e_1_2_11_32_2","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1161\/01.CIR.95.8.2007","article-title":"Effect of single drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents","volume":"95","author":"Gottdiener JS","year":"1997","journal-title":"Circulation"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.88.5.2277"},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.10.1295"},{"key":"e_1_2_11_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)09374-X"},{"key":"e_1_2_11_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.4.1731"},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"e_1_2_11_38_2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin\u2010converting\u2010enzyme inhibitor benazepril on the progression of chronic renal insufficiency","volume":"34","author":"Maschio G","year":"1996","journal-title":"N Engl J Med"},{"key":"e_1_2_11_39_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-5-199709010-00001"},{"key":"e_1_2_11_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301"},{"issue":"6","key":"e_1_2_11_41_2","first-page":"E28","article-title":"Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy","volume":"36","author":"Svensson P","year":"2001","journal-title":"Hypertension"},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.15.3.327"},{"issue":"5","key":"e_1_2_11_43_2","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/00005344-199000005-00010","article-title":"Effects of captopril on atherosclerosis in cynomolgus monkeys","volume":"15","author":"Aberg G","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_2_11_44_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.14.1411"},{"key":"e_1_2_11_45_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0895-7061(00)01257-7","article-title":"Left ventricular hypertrophy and angiotensin II antagonists","volume":"14","author":"Dahloff B","year":"2001","journal-title":"Am J Hypertens"},{"key":"e_1_2_11_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.20.2658"},{"issue":"1","key":"e_1_2_11_47_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1742-1241.2000.tb11833.x","article-title":"A study of the efficacy and safety of irbesartan in combination with conventional therapy. Irbesartan Heart Failure Group","volume":"54","author":"Tonkon M","year":"2000","journal-title":"Intern J Clin Pract"},{"key":"e_1_2_11_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(99)70008-6"},{"key":"e_1_2_11_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-9842(00)00060-X"},{"issue":"3","key":"e_1_2_11_50_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000007023","article-title":"Hemodynamic and hormonal effects of angiotensin II antagonist, candesartan cilexetil in patients with congestive heart failure","volume":"93","author":"Yoshimuira M","year":"2000","journal-title":"Cardiology"},{"key":"e_1_2_11_51_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.88.4.1602"},{"key":"e_1_2_11_52_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.3.691"},{"key":"e_1_2_11_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(00)90037-1"},{"key":"e_1_2_11_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01187-2"},{"key":"e_1_2_11_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02213-3"},{"key":"e_1_2_11_56_2","first-page":"1667","article-title":"A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn J, Tognoni G, and Val\u2010HeFT Investigators","year":"2002","journal-title":"N Engl J Med"},{"key":"e_1_2_11_57_2","doi-asserted-by":"crossref","first-page":"137A","DOI":"10.1016\/S0895-7061(97)89157-1","article-title":"Effects of losartan on cardiac performance during treadmill exercise in hypertensive subjects [abstract]","volume":"10","author":"Cottone C","year":"1997","journal-title":"Am J Hypertens"},{"key":"e_1_2_11_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00253-2"},{"key":"e_1_2_11_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"e_1_2_11_60_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"e_1_2_11_61_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.10.1056"},{"issue":"9335","key":"e_1_2_11_62_2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high\u2010risk patients after acute myocardial infarction: the OPTIMAAL randomized trial","volume":"360","author":"Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee of the OPTIMAAL Study Group","year":"2002","journal-title":"Lancet"},{"key":"e_1_2_11_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.12.1492"},{"issue":"1","key":"e_1_2_11_64_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00004872-200201000-00011","article-title":"Effect of crossing over hypertensive patients from a beta\u2010blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function","volume":"20","author":"Schiffrin EL","year":"2002","journal-title":"J Hypertens"},{"key":"e_1_2_11_65_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.14.1653"},{"issue":"2","key":"e_1_2_11_66_2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/01.HYP.34.4.969","article-title":"AT\u20101 receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits","volume":"34","author":"Heras N","year":"1999","journal-title":"Hypertension"},{"key":"e_1_2_11_67_2","first-page":"93","article-title":"Valsartan for prevention of restenosis after stenting type B2\/C lesions: the Val\u2010PREST trial","volume":"13","author":"Peters S","year":"2001","journal-title":"J Invas Cardiol"},{"issue":"6","key":"e_1_2_11_68_2","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1097\/00005344-199312050-00010","article-title":"Study of antiatherogenic properties of indapamide, a pharmacologic model","volume":"22","author":"Lebrillant E","year":"1993","journal-title":"J Cardio Pharm"},{"key":"e_1_2_11_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(00)00262-4"},{"key":"e_1_2_11_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)01200-5"},{"key":"e_1_2_11_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)00333-6"},{"key":"e_1_2_11_72_2","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.5.1.17"},{"key":"e_1_2_11_73_2","first-page":"55","article-title":"Long\u2010term effects of enalapril monotherapy and enalapril\/hydrochlorothiazide combination therapy on blood pressure, renal function, and body fluid composition","volume":"2","author":"Reams GP","year":"1986","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"e_1_2_11_74_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1996.00440030072009"},{"key":"e_1_2_11_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)89033-4"},{"key":"e_1_2_11_76_2","first-page":"654","volume-title":"Physician's Desk Reference","year":"2001"},{"key":"e_1_2_11_77_2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/archinte.1997.00440270080007","article-title":"Relationships of quality of life measures to long term lifestyle and drug treatment in the Treatment of Mild Hypertension Study","volume":"157","author":"Grimm RH","year":"1997","journal-title":"Arch Intern Med"},{"key":"e_1_2_11_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(96)00253-1"},{"key":"e_1_2_11_79_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.99.1.36"},{"key":"e_1_2_11_80_2","first-page":"156","article-title":"Choice of initial antihypertensive medication may influence the extent to which patients stay on therapy: a community\u2010based study of losartan\u2010based regimen vs. usual care","volume":"7","author":"Moore MA","year":"1998","journal-title":"High Blood Press"},{"key":"e_1_2_11_81_2","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00000441-200105000-00006","article-title":"Sexual dysfunction in hypertensive patients treated with losartan","volume":"321","author":"Vidal JLL","year":"2001","journal-title":"Am J Med Sci"},{"key":"e_1_2_11_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(80)90145-6"},{"key":"e_1_2_11_83_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.35.5.1025"},{"key":"e_1_2_11_84_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.26.1.112"},{"key":"e_1_2_11_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)80446-4"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1524-6175.2003.01040.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1524-6175.2003.01040.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:48:15Z","timestamp":1697230095000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1524-6175.2003.01040.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1111\/j.1524-6175.2003.01040.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1524-6175.2003.01040.x","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3]]}}}